openPR Logo
Press release

Lysosomal Acid Lipase (LAL) Deficiency Treatment Market : Analysis and Forecast by 2024

Lysosomal Acid Lipase (LAL) Deficiency Treatment Market :

The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesterol esters and triglycerides. Patients with LAL deficiency have no or little LAL enzyme activity which results in the accumulation of fats within various body cells that leads to high cholesterol and triglycerides, and a very low HDL-cholesterol level. There are two main types of LAL disorder: early onset Wolman Disease and late onset CESD. Wolman disease is very rare, with an incidence of less than one in 100,000 live births. CESD is a less severe, later-onset disorder which can occur in adults at any stage in life, having an incidence of about one in 25 per million births. While Wolman disease is a relatively occurrence, the infants affected with it usually die within the first year of birth after experiencing growth failure, liver fibrosis, and cirrhosis. In late onset LAL deficiency, the accumulation of cholesteryl esters and triglycerides in blood vessels, vital organs, and other tissues of adults, results in progressive and multiple-organ damage which includes fibrosis, cirrhosis, liver failure, accelerated atherosclerosis, and cardiovascular disease. Since LAL disease has symptoms similar to many other diseases, for instance, heart disease, it is often misdiagnosed. The disease in its late onset form does not affect everyone equally and thus symptoms can vary from person to person, often manifesting as mild symptoms which consequently also makes the disease underdiagnosed worldwide. The biggest factor that shall drive the market is that currently, apart from a recently approved drug by U.S. FDA known as Kanuma (sebelipase alfa), there is no approved treatment available for the disease. Thus, tremendous business opportunity lies in the investment of finding therapies for treatment in this market. Lack of awareness regarding disease diagnosis and untimely treatment due to ignorance of symptoms may restrain the growth of the market.

Request Sample Copy of the Report@

 https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15329

The global market for lysosomal acid lipase (LAL) deficiency is segmented on basis of type of therapy, type of drug, disease indication and geography:

Segmentation by Type of Therapy (no. of surgeries)
Liver Transplant
Hematopoietic Stem Cell Transplant
Segmentation by Type of Drug
Statins and other dyslipidemia drugs
Sebelipase alfa (Kanuma)
Segmentation by Disease Indication
Wolman Disease
Cholesteryl ester storage disease (CESD)
LAL deficiency is a chronic progressive genetic metabolic disease associated with substantial morbidity as well as premature mortality. It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million of the general population. The current management practice for the disease involves taking lipid lowering medications such as statins, to overcome symptoms of lipid accumulation. However, progression of the disease often necessitates the patient to undergo a liver transplant. The market for lysosomal acid lipase (LAL) deficiency is segmented based on number of surgeries: for liver transplant and for hematopoietic stem cell transplant.  A liver transplant may give LAL patients respite from liver failure, but it does not tackle the underlying cause of the disease and may not stop disease progression in extra-hepatic organs, which include the heart and kidneys. However, it is still an option for patients who wish to increase chances of survival. Although hematopoietic stem cell transplant has been performed in a few infants with lysosomal acid lipase (LAL) deficiency, it has been associated with complications and the long term outcomes are unknown. Thus, the liver transplant segment shall witness more number of surgeries during the forecast period compared to the hematopoietic stem cell transplant segment. 

Based on disease indication, sebalipase alfa segment is expected to contribute largest share in global lysosomal acid lipase (LAL) deficiency treatment market due to it being the only approved mainstay treatment for the disease. Statins although helpful in symptom management for lysosomal acid lipase (LAL) deficiency, are not effective in completely preventing the progression of the disease, resulting in their estimated lower share in the market compared to sebalipase alfa. Moreover, the value garnering segment would be sebalipase alfa due to its higher cost of treatment and also being the preferred treatment due to it being the only approved drug for this indication. On the basis of disease indication, the market has been segmented into wolman disease and cholesteryl ester storage disease (CESD). The market for CESD is anticipated to be higher due to comparatively higher need in this segment.

On the basis of regional presence, global lysosomal acid lipase (LAL) deficiency treatment market is segmented into five key regions viz.  North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe are expected to lead the global lysosomal acid lipase (LAL) deficiency treatment market due to high prevalence of this rare disease.

Request TOC of the Report@

 https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=15329

Some of the major players in global lysosomal acid lipase (LAL) deficiency treatment market are Alexion Pharmaceutical Inc., AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.

The report covers exhaustive analysis on:

Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Segments
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Dynamics
Historical Actual Market Size, 2013 - 2015
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Size & Forecast 2016 to 2024
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Current Trends/Issues/Challenges
Competition & Companies involved
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Drivers and Restraints
Regional analysis includes

North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lysosomal Acid Lipase (LAL) Deficiency Treatment Market : Analysis and Forecast by 2024 here

News-ID: 724295 • Views: 333

More Releases from Transparency Market Research

Potassium Bicarbonate Market Technological breakthroughs, Value chain and stakeh …
Overview TMR’s report on the Potassium Bicarbonate Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Potassium Bicarbonate serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Potassium Bicarbonate over the forecast period. These indicators help businesses
Liquid Analytical Instruments Market Global Market Opportunity Assessment Study …
Overview TMR’s report on the Liquid Analytical Instruments Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Liquid Analytical Instruments serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Liquid Analytical Instruments over the forecast period. These
Boron Oxide Market Growth Prospects, Trends and Forecast up to 2023
Overview TMR’s report on the Boron Oxide Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Boron Oxide serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Boron Oxide over the forecast period. These indicators help businesses
Hydrochloric Acid Market to Witness a Pronounce Growth During 2016 - 2024
Overview TMR’s report on the Hydrochloric Acid Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Hydrochloric Acid serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Hydrochloric Acid over the forecast period. These indicators help businesses

All 5 Releases


More Releases for LAL

Talk on Corrosion & Electrochemistry at Banasthali by Dr S Lal Plating Consultan …
According to NASA, the cost of corrosion to the USA is around $276 billion per year and this very statement itself is enough to drive the importance of this field of study. Dr Sudarshan Lal Sharma is presently a Plating consultatnt at Mechanicsburg, Pennsylvania – PA USA. He holds a Masters with a first rank in Physical Chemistry from Vikram University Ujjain, PhD in Electro Analytical Chemistry from Agra University and
Ram Lal Ram Chandra India Ltd excited to launch its new Brand ShiBui BAGS Backpa …
Shibui bags exclusively enter into the marketplace of Amazon. The idea of the Shibuibags is to offer a product that reflects the values of customer comfort, style, colour and individuality. Shibui will provide the best quality of backpacks, laptops bags, sling bags, wallets and travel bags. Our bags are exclusive and modernized. Our major focus will be on giving lifestyles backpacks which are designed to be elegant and make a style. The
Global Laser-assisted Liposuction (LAL) Equipment Market 2018 - Syneron, Cutera, …
Apex Market Reports, recently published a detailed market research study focused on the “Laser-assisted Liposuction (LAL) Equipment Market” across the global, regional and country level. The report provides 360° analysis of “Laser-assisted Liposuction (LAL) Equipment Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market: Business Intelligence & …
The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market : Growth, Demand and Key …
The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Research Report: Analysi …
The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis